Alx Oncology Holdings Inc (ALXO)

$1.17 +0.14 (13.59%)
Market Cap 62.66M
Revenue (ttm) 0.00
Net Income (ttm) -134.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 2,878,100
Avg Vol 1,012,582
Day's Range N/A - N/A
Shares Out 53.55M
Stochastic %K 97%
Beta 1.14
Analysts Strong Sell
Price Target $2.25

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 466 7125
Address:
323 Allerton Avenue, South San Francisco, United States
neueinvestor
neueinvestor Aug. 23 at 10:52 PM
$ALXO 100?
0 · Reply
StockScanners
StockScanners Aug. 23 at 6:54 PM
$ALXO reached 1.19, we might not get pullbacks on all of them, but one thing for sure is many times we are at the right spot before a move up, lets get it team, if you know how to trade breakouts then spotting opportunity as it rises should be easy
1 · Reply
Bullisch_150
Bullisch_150 Aug. 23 at 3:20 PM
$ALXO monday
1 · Reply
TriggerTamer
TriggerTamer Aug. 23 at 5:25 AM
$ALXO Alx Oncology Holdings is a clinical stage immuno-oncology company with pivotal data readouts approaching
0 · Reply
neueinvestor
neueinvestor Aug. 23 at 12:10 AM
$ALXO
0 · Reply
algo888
algo888 Aug. 22 at 8:16 PM
$ALXO 2,500,459 Buys or 88% scalping crooks holding price down
0 · Reply
BadyBady
BadyBady Aug. 22 at 8:02 PM
$ALXO Day2😍😎
0 · Reply
algo888
algo888 Aug. 22 at 7:55 PM
$ALXO not getting filled @ the Bid??? LOL
0 · Reply
algo888
algo888 Aug. 22 at 7:49 PM
$ALXO too risky to buy now @ 1.20 wait for 1.50 - 1.60 range AH's then Go ALL IN
0 · Reply
GrowthMindset247
GrowthMindset247 Aug. 22 at 7:47 PM
$ALXO and there go these prices 💹🙌
0 · Reply
Latest News on ALXO
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

Aug 19, 2025, 8:00 AM EDT - 4 days ago

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:45 PM EDT - 11 days ago

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 11 days ago

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

Aug 5, 2025, 8:00 AM EDT - 18 days ago

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 30, 2025, 8:00 AM EDT - 3 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 20, 2025, 8:00 AM EDT - 3 months ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 13, 2025, 8:00 AM EDT - 3 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:30 AM EDT - 3 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025, 8:00 AM EDT - 4 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 1:10 PM EDT - 4 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Apr 25, 2025, 9:00 AM EDT - 4 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:01 PM EST - 6 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Mar 5, 2025, 8:00 AM EST - 6 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 27, 2025, 8:00 AM EST - 6 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Feb 18, 2025, 8:00 AM EST - 6 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 23, 2025, 8:00 AM EST - 7 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 22, 2025, 4:01 PM EST - 7 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Jan 21, 2025, 5:00 PM EST - 7 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Dec 18, 2024, 8:00 AM EST - 8 months ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 14, 2024, 8:00 AM EST - 10 months ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:00 PM EST - 10 months ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Nov 1, 2024, 5:30 PM EDT - 10 months ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Sep 11, 2024, 10:36 PM EDT - 1 year ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Aug 6, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Appoints Allison Dillon as Chief Business Officer

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:03 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

ALX Oncology shares jump 9% after Jefferies upgrade

Dec 8, 2023, 8:30 AM EST - 1 year ago

ALX Oncology shares jump 9% after Jefferies upgrade

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 4:05 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 10, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 9, 2023, 12:38 AM EDT - 2 years ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

ALX Oncology Announces Pricing of Public Offering

Oct 5, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Announces Pricing of Public Offering

ALX Oncology Announces Proposed Public Offering

Oct 4, 2023, 4:10 PM EDT - 2 years ago

ALX Oncology Announces Proposed Public Offering

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 3, 2023, 6:00 AM EDT - 2 years ago

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 2, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology Realigns Executive Leadership Team

Sep 6, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Realigns Executive Leadership Team

ALX Oncology Announces September Investor Conference Participation

Aug 31, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Announces September Investor Conference Participation

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Aug 10, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

Jun 26, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 11, 2023, 4:01 PM EDT - 2 years ago

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

May 9, 2023, 7:00 AM EDT - 2 years ago

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

Mar 14, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

neueinvestor
neueinvestor Aug. 23 at 10:52 PM
$ALXO 100?
0 · Reply
StockScanners
StockScanners Aug. 23 at 6:54 PM
$ALXO reached 1.19, we might not get pullbacks on all of them, but one thing for sure is many times we are at the right spot before a move up, lets get it team, if you know how to trade breakouts then spotting opportunity as it rises should be easy
1 · Reply
Bullisch_150
Bullisch_150 Aug. 23 at 3:20 PM
$ALXO monday
1 · Reply
TriggerTamer
TriggerTamer Aug. 23 at 5:25 AM
$ALXO Alx Oncology Holdings is a clinical stage immuno-oncology company with pivotal data readouts approaching
0 · Reply
neueinvestor
neueinvestor Aug. 23 at 12:10 AM
$ALXO
0 · Reply
algo888
algo888 Aug. 22 at 8:16 PM
$ALXO 2,500,459 Buys or 88% scalping crooks holding price down
0 · Reply
BadyBady
BadyBady Aug. 22 at 8:02 PM
$ALXO Day2😍😎
0 · Reply
algo888
algo888 Aug. 22 at 7:55 PM
$ALXO not getting filled @ the Bid??? LOL
0 · Reply
algo888
algo888 Aug. 22 at 7:49 PM
$ALXO too risky to buy now @ 1.20 wait for 1.50 - 1.60 range AH's then Go ALL IN
0 · Reply
GrowthMindset247
GrowthMindset247 Aug. 22 at 7:47 PM
$ALXO and there go these prices 💹🙌
0 · Reply
algo888
algo888 Aug. 22 at 7:43 PM
$ALXO 1.20 Shorts on FOMO = panic buying
0 · Reply
algo888
algo888 Aug. 22 at 7:40 PM
$ALXO Dont cry you never got alerted in the .90's yesterday when pps is already @ $5.45 https://www.tradingview.com/x/7MZvJsfI/
0 · Reply
algo888
algo888 Aug. 22 at 7:32 PM
$ALXO slap the ASK only .03 cents away to HOD
0 · Reply
algo888
algo888 Aug. 22 at 7:29 PM
$ALXO 1.20 Booooom it
0 · Reply
algo888
algo888 Aug. 22 at 7:25 PM
$ALXO last chance to load up quietly below 1.20
0 · Reply
algo888
algo888 Aug. 22 at 7:24 PM
$ALXO Huge bid ready to push it above 1.20 Send it
0 · Reply
algo888
algo888 Aug. 22 at 7:05 PM
$ALXO 1.50 - 1.60 push AH's
0 · Reply
algo888
algo888 Aug. 22 at 6:56 PM
$ALXO .04 cents away to trigger FOMO above 1.20 LOL
0 · Reply
algo888
algo888 Aug. 22 at 6:43 PM
$ALXO wild imagination... you never look back after it has broken above the mother of all resistance, That would be a Bearish move.. You go forward not backwards... You're an example of a Fake Bull
2 · Reply
GrowthMindset247
GrowthMindset247 Aug. 22 at 6:42 PM
$ALXO 🫰🫰🫰🫰🫰
0 · Reply
StarLord13
StarLord13 Aug. 22 at 6:33 PM
$ALXO As much as I’d love this to run from here, I’m half expecting it to pull back to test the 200SMA in the .90’s like it did with the 50 and 100MA before continuation higher.
0 · Reply
algo888
algo888 Aug. 22 at 6:25 PM
$ALXO price climbing gradually since .61 and it is already up 98% nothing has changed except insiders loading up for the massive explosion to the upside.... they wont realease news until they are already fully loaded up... Daily forming a massive Bullish expansion..
0 · Reply